We are live on ! Find out more
RCUS icon

Arcus Biosciences

157 hedge funds and large institutions have $1.59B invested in Arcus Biosciences in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $11.1M

79% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 19

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

11% more funds holding

Funds holding: 142157 (+15)

1.11% less ownership

Funds ownership: 72.35%71.25% (-1.1%)

20% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 55

23% less capital invested

Capital invested by funds: $2.06B → $1.59B (-$468M)

Holders
157
Holders Change
+15
Holders Change %
+10.56%
% of All Funds
2.48%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
34
Increased
44
Reduced
55
Closed
19
Calls
$23.4M
Puts
$11.1M
Net Calls
+$12.3M
Net Calls Change
+$15.5M
Name Holding Trade Value Shares
Change
Change in
Stake
American Century Companies
51
American Century Companies
Missouri
$3.71M +$64K +1,911 +2%
BG
52
Bellevue Group
Switzerland
$3.52M +$811K +24,200 +28%
Squarepoint
53
Squarepoint
New York
$3.21M +$2.82M +84,281 +484%
SG Americas Securities
54
SG Americas Securities
New York
$2.97M +$2.29M +68,297 +264%
Swiss National Bank
55
Swiss National Bank
Switzerland
$2.88M +$161K +4,800 +6%
PA
56
Parallel Advisors
California
$2.83M +$838 +25 +0%
Adage Capital Partners
57
Adage Capital Partners
Massachusetts
$2.37M
AA
58
ALPS Advisors
Colorado
$2.31M -$277K -8,255 -10%
PPA
59
Parametric Portfolio Associates
Washington
$2.3M +$637K +19,018 +35%
APP
60
Alpha Paradigm Partners
Illinois
$2.1M +$2.23M +66,508 New
PCC
61
Park Circle Company
Maryland
$2.02M
PIM
62
Platinum Investment Management
Australia
$1.95M
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$1.92M -$154K -4,597 -7%
State of Wisconsin Investment Board
64
State of Wisconsin Investment Board
Wisconsin
$1.79M -$268K -8,000 -12%
LOAMS
65
Lombard Odier Asset Management (Switzerland)
Switzerland
$1.78M +$1.89M +56,484 New
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
$1.66M -$164K -4,882 -8%
First Trust Advisors
67
First Trust Advisors
Illinois
$1.64M -$3.58M -106,838 -67%
HS
68
HighVista Strategies
Massachusetts
$1.58M +$1.68M +50,050 New
CSS
69
Cubist Systematic Strategies
Connecticut
$1.54M -$585K -17,464 -26%
DekaBank Deutsche Girozentrale
70
DekaBank Deutsche Girozentrale
Germany
$1.44M +$131K +3,900 +10%
SEI Investments
71
SEI Investments
Pennsylvania
$1.43M -$161K -4,816 -10%
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
$1.39M -$9.68M -288,907 -87%
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$1.33M +$314K +9,375 +29%
E
74
Ergoteles
New York
$1.26M +$1.34M +39,966 New
DFCM
75
Dark Forest Capital Management
Puerto Rico
$1.22M +$1.29M +38,588 +25,898%

RCUS Hedge Fund Activity: Q1 2022 in Review

157 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2022, worth a combined $1.59B — down 23% from $2.06B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new RCUS positions and 19 closed out — a net gain of 15 holders — while 44 added to existing stakes and 55 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $34.4M. The largest seller was EcoR1 Capital, cutting an estimated $75.7M.

  • 157 institutional investors held Arcus Biosciences (RCUS) as of Q1 2022, up from 142 in Q4 2021.
  • Funds reported $1.59B of Arcus Biosciences stock for Q1 2022, down 23% quarter-over-quarter.
  • 34 funds opened new Arcus Biosciences positions in Q1 2022 and 19 closed out, a net change of +15 holders.
  • The largest Arcus Biosciences buyer in Q1 2022 was AllianceBernstein, an estimated $34.4M added.
  • The largest Arcus Biosciences seller in Q1 2022 was EcoR1 Capital, an estimated $75.7M sold.

Based on aggregated 13F filings for Q1 2022.